Detalles de la búsqueda
1.
Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
J Antimicrob Chemother
; 76(11): 2833-2838, 2021 10 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34436603
2.
Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
Antimicrob Agents Chemother
; 62(1)2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29109163
3.
Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection.
Antimicrob Agents Chemother
; 61(10)2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28784674
4.
Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility.
Antimicrob Agents Chemother
; 60(5): 3174-7, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26926647
5.
Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.
Antimicrob Agents Chemother
; 59(4): 2405-9, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25666152
6.
In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020.
Infect Drug Resist
; 17: 343-354, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38312522
7.
In vitro activity of aztreonam-avibactam and comparators against Metallo-ß-Lactamase-producing Enterobacterales from ATLAS Global Surveillance Program, 2016-2020.
J Glob Antimicrob Resist
; 36: 123-131, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38154750
8.
Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.
Antimicrob Agents Chemother
; 57(1): 205-11, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23089749
9.
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016-2020.
Antibiotics (Basel)
; 12(11)2023 Nov 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37998793
10.
Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci.
J Antimicrob Chemother
; 72(2): 622-624, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27856721
11.
Ceftazidime-avibactam activity against Gram-negative respiratory isolates collected between 2018 and 2019.
J Glob Antimicrob Resist
; 31: 239-247, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36208850
12.
Antimicrobial Activity of Ceftazidime-Avibactam and Comparators Against Fluoroquinolone-Resistant Klebsiella pneumoniae Collected Globally from Antimicrobial Testing Leadership and Surveillance: 2018-2019.
Microb Drug Resist
; 28(11): 1019-1027, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36251881
13.
In vitro activity of aztreonam/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019.
J Glob Antimicrob Resist
; 30: 214-221, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35760303
14.
Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012-2017.
J Glob Antimicrob Resist
; 24: 316-320, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33524556
15.
Assessment of oritavancin serum protein binding across species.
Antimicrob Agents Chemother
; 54(8): 3481-3, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20498314
16.
Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
Antimicrob Agents Chemother
; 54(12): 5369-71, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20876372
17.
Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis.
Bioorg Med Chem Lett
; 20(4): 1355-9, 2010 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20097069
18.
Inhibition of transcription in Staphylococcus aureus by a primary sigma factor-binding polypeptide from phage G1.
J Bacteriol
; 191(12): 3763-71, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19376864
19.
Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
Antimicrob Agents Chemother
; 53(3): 918-25, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19104027
20.
Impact of human serum albumin on oritavancin in vitro activity against enterococci.
Antimicrob Agents Chemother
; 53(6): 2687-9, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19349514